Conferences

Conferences

SITC 2018
Pegfilgrastim, but not Plinabulin, Generates a Blood Myeloid Cell (BMC) Repertoire with a Predominant Immunosuppressive Phenotype

ESMO 2018
Plinabulin (Plin), a Novel non-G-CSF Molecule for the Prevention of Chemotherapy-Induced Neutropenia (CIN), has the Potential to Positively Impact Tumor Micro Environment

SLB 2018
Plinabulin-Associated Neutrophil Demargination: Evidence for a Clinically Relevant Mechanism of Action for the Prevention of Chemotherapy-Induced-Neutropenia

IASLC 2018
Plinabulin, a Novel Immuno-Oncology Agent mitigates Docetaxel Chemotherapy – Induced-Neutropenia and – Thrombocytopenia in NSCLC Patients

ASCO 2018
Plinabulin (Plin), a small molecule with anti-cancer activity and a novel mechanism of action (MoA) in docetaxel (Tax) induced neutropenia: Phase (φ) 2 results from a head-to-head comparison with Pegfilgrastim (Peg)

AACR 2018
Plinabulin ameliorates chemotherapy-induced neutropenia: Mechanistic insights

Keystone 2017
Guanine nucleotide exchange factor-H1 signaling is critical for induction of anti-tumor immunity induced by microtubule-depolymerizing drugs

ASCO-SITC 2017
Plinabulin is a small molecule clinical stage immune-oncology agent for NSCLC

ASH 2016
Plinabulin, a Novel Small Molecule That Ameliorates Chemotherapy-Induced Neutropenia, Is Administered on the Same Day of Chemotherapy and Has Anticancer Efficacy

AACR TME 2016
Plinabulin: Evidence for an Immune-mediated Mechanism of Action